Janssen to help launch Castleman disease patient registry

Janssen will be working with the Castleman Disease Collaborative Network and the University of Pennsylvania to launch the first ever global patient registry for Castleman disease.

The natural history registry will help patients with Castleman disease to contribute their own personal medical information to advance the knowledge of the disease, including its diagnosis and treatment.

To be known as ACCELERATE, the registry will collect data on longitudinal changes in the disease over time, allowing patients in the US and other countries outside Europe to enrol themselves and send their medical records to be entered into the registry.

In Europe, meanwhile, ACCELERATE will work with ten clinical sites to collect patient data, accounting for the fact that different regulations govern the use of patient information in the EU.

Dr Craig Tendler, vice-president of late-stage development and global medical affairs for oncology, haematology and supportive care at Janssen Research and Development, said: "We believe this registry will help transform our collective understanding and approach to treating Castleman disease. We are honoured to be a part of this groundbreaking initiative."

Castleman disease is a serious immune system disorder that can be difficult to diagnose due to the similarity of its symptoms to other diseases and conditions. The exact cause of the condition is also unknown, meaning treatment options remain scarce.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.